Skip to main content

Thyroid Cancer

Cabometyx Receives FDA Approval for Differentiated Thyroid Cancer
FDA Approvals, News & Updates, Thyroid Cancer
October 2021, Vol 11, No 10
On September 17, 2021, the FDA accelerated the approval of a new indication for cabozantinib (Cabometyx; Exelixis) for the treatment of patients aged ≥12 years with locally advanced or metastatic differentiated thyroid cancer that has progressed after VEGFR-targeted therapy and who are ineligible for, or whose disease is refractory to, radioactive iodine. The FDA granted cabozantinib breakthrough therapy and orphan drug designations for this indication. Read More ›
In the Literature
In the Literature, Leukemia, Lung Cancer, Thyroid Cancer
Web Exclusives
Selpercatinib Shows Durable Responses in Patients with Thyroid Cancer and RET Mutation
Venclexta plus Azacitidine Improves Overall Survival in Patients with AML
Advances in New Therapies Attributed to Reductions in Lung Cancer Mortality
Read More ›
FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib
By Yvette Florio Lane
FDA Approvals, News & Updates, Lung Cancer, Thyroid Cancer, In the Literature
Web Exclusives
On January 29, 2020, Eli Lilly announced that the FDA granted priority review to their New Drug Application for selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion-positive non–small-cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. The FDA is aiming to provide its decision on the approval of selpercatinib in the third quarter of 2020. Read More ›